Senolytic therapeutics market seen doubling by 2030

The Business Research Company says the global senolytic and anti-aging therapeutics market is set to grow from $2.18 billion in 2025 to $5.31 billion by 2030, driven by aging populations, more research funding and rising interest in preventive care. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Senolytic and anti-aging therapeutics target aging cells and the biological processes tied to age-related disease. - The market’s growth points to rising demand for treatments aimed at healthier aging, not just longer lifespans. - The category could reshape drug development, especially in preventive care and geriatric medicine.

What happened: - The Business Research Company released a report titled The Business Research Company’s Senolytic And Anti-Aging Therapeutics Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report estimates the market will rise from $2.18 billion in 2025 to $2.6 billion in 2026. - The report projects the market will reach about $5.31 billion by 2030. - The report covers regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - The report puts the market’s 2025-2026 CAGR at 19.2%. - The report projects a 19.5% CAGR through 2030. - Growth is linked to more age-related degenerative diseases, limited success from traditional regenerative treatments, a growing elderly population, higher funding for cellular senescence research and more early-stage longevity biotech companies. - The report highlights breakthroughs in senescent-cell clearing technologies, artificial intelligence in anti-aging drug discovery, personalized medicine for geriatric patients, preventive healthcare demand and increasing clinical validation of senolytic therapies. - Key future trends include geroscience-driven drug development, diagnostics for senescence-associated biomarkers, precision longevity treatments, preventive anti-aging care and combination therapies using senolytic and senomorphic approaches. - The report defines senolytic and anti-aging therapeutics as treatments that selectively remove senescent cells or slow biological aging to improve tissue function and reduce cellular damage and inflammation. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the projected period. - The report links North America’s lead to advanced healthcare infrastructure and strong research capabilities.

Between the lines: - The market story is being driven by demographics and science at the same time. - A larger older population creates demand, while advancing research is making longevity-focused therapies more commercially plausible. - The emphasis on biomarkers, AI and combination therapies suggests the field is moving from broad anti-aging concepts toward more targeted clinical applications.

What's next: - The market is expected to continue expanding as senescent-cell therapies gain more validation and personalized approaches mature. - Asia-Pacific’s rapid growth could make the region a bigger competitive focus for developers and investors. - The report’s forecast timeline extends through 2035, signaling continued long-term interest in the category.